Expression of TGFβ1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin

Oncology Reports

Volumn 25, Issue 4, 2011, Pages 1131-1138

  Komiyama, Shinichi ^a,b   Kurahashi, Takashi ^b   Ishikawa, Mitsuya ^b   Tanaka, Kyoko ^b,c   Komiyama, Mizuka ^a   Mikami, Mikio ^b,d   Udagawa, Yasuhiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA NATIONAL HOSPITAL   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY   (Japan)

Author keywords

Biomarker; Carboplatin; Ovarian cancer; Paclitaxel; Prognosis; TGF receptor; TGF 1

Indexed keywords

CARBOPLATIN; MESSENGER RNA; PACLITAXEL; RIBONUCLEASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TRANSFORMING GROWTH FACTOR BETA1; ANTINEOPLASTIC AGENT; PROTEIN SERINE THREONINE KINASE; TGF BETA TYPE I RECEPTOR; TGF-BETA TYPE I RECEPTOR; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA TYPE II RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; HUMAN; HUMAN TISSUE; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UTERINE TUBE CARCINOMA; COLLOID CARCINOMA; CYSTADENOCARCINOMA; DRUG RESISTANCE; ENZYME IMMUNOASSAY; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PERITONEUM TUMOR; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; UTERINE TUBE TUMOR;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79952209001     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1151     Document Type: Article

References (39)

1. Winter WE III, Maxwell GL, Tian C, et al: Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 3621-3627, 2007. (Pubitemid 47372600)
2. Morgan RJ Jr, Alvarez RD, Armstrong DK, et al: National Comprehensive Cancer Network. Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 6: 766-794, 2008.
3. Herzog TJ and Pothuri B: Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol 3: 604-611, 2006. (Pubitemid 44669715)
4. Ozols RF: Challenges for chemotherapy in ovarian cancer. Ann Oncol 17 (Suppl 5): v181-v187, 2006.
5. Bukowski RM, Ozols RF and Markman M: The Management of recurrent ovarian cancer. Semin Oncol 34 (Suppl 2): 1-15, 2007.
6. Shih Ie M and Kurman RJ: Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164: 1511-1518, 2004.
7. Takano M, Kikuchi Y, Yaegashi N, et al: Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94: 1369-1374, 2006. (Pubitemid 43772268)
8. Shimada M, Kigawa J, Ohishi Y, et al: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 113: 331-334, 2009.
9. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584, 2003. (Pubitemid 37280136)
10. Bierie B and Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506-520, 2006. (Pubitemid 43980540)
11. Massague J: TGFbeta in cancer. Cell 134: 215-230, 2008.
12. Pardali K and Moustakas A: Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer. Biochim Biophys Acta 1775: 21-62, 2007. (Pubitemid 44881193)
13. Do TV, Kubba LA, Du H, Sturgis CD and Woodruff TK: Transforming growth factor-beta1, transforming growth factor-beta2, and transforming growth factor-beta3 enhance ovarian cancer metastatic potential by inducing a Smad3-dependent epithelial-to-mesenchymal transition. Mol Cancer Res 6: 695-705, 2008.
14. Robson H, Anderson E, James RD and Schofield PF: Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74: 753-758, 1996. (Pubitemid 26300767)
15. Teicher BA, Ikebe M, Ara G, Keyes SR and Herbst RS: Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 11: 463-472, 1997. (Pubitemid 28071451)
16. Bennett WP, el-Deiry WS, Rush WL, et al: p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res 4: 1499-1506, 1998. (Pubitemid 28265234)
17. Benson JR: Role of transforming growth factor beta in breast carcinogenesis. Lancet Oncol 5: 229-239, 2004.
18. Vagenas K, Spyropoulos C, Gavala V and Tsamandas AC: TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. J Surg Res 139: 182-188, 2007. (Pubitemid 46551168)
19. Bookman MA for the Gynecologic Cancer InterGroup (GCIG) through the Gynecologic Oncology Group (GOG): GOG182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs. combinations with gemcitabine (G), PEG-liposomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma. J Clin Oncol 24 (Suppl): 456, 2006.
20. Gil-Guerrero L, Dotor J, Huibregtse IL, et al: In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-beta1. J Immunol 181: 126-135, 2008.
21. Korpal M and Kang Y: Targeting the transforming growth factor-beta signalling pathway in metastatic cancer. Eur J Cancer 46: 1232-1240, 2010.
22. Nagaraj NS and Datta PK: Targeting the transforming growth factor-beta signaling pathway in human cancer. Expert Opin Investig Drugs 19: 77-91, 2010.
23. Haider SK, Beauchamp RD and Datta PK: A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. Neoplasia 7: 509-521, 2005. (Pubitemid 40791869)
24. Bandyopadhyay A, Agyin JK, Wang L, et al: Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 66: 6714-6721, 2006. (Pubitemid 44085629)
25. Ehata S, Hanyu A, Fujime M, et al: Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98: 127-133, 2007. (Pubitemid 44803931)
26. Hau P, Jachimczak P and Bogdahn U: Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev Anticancer Ther 9: 1663-1674, 2009.
27. Zhang B, Haider SK, Zhang S and Datta PK: Targeting transforming growth factor-beta signaling in liver metastasis of colon cancer. Cancer Lett 277: 114-120, 2009.
28. Nemunaitis J, Nemunaitis M, Senzer N, et al: Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16: 620-624, 2009.
29. Shinto O, Yashiro M, Kawajiri H, et al: Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Br J Cancer 102: 844-851, 2010.
30. Cardillo MR, Yap E and Castagna G: Molecular genetic analysis of TGF-beta1 in ovarian neoplasia. J Exp Clin Cancer Res 16: 49-56, 1997. (Pubitemid 27189708)
31. Lynch MA, Nakashima R, Song H, et al: Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res 58: 4227-4232, 1998. (Pubitemid 28450015)
32. Wang D, Kanuma T, Mizunuma H, et al: Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res 60: 4507-4512, 2000. (Pubitemid 32103632)
33. Chen T, Triplett J, Dehner B, et al: Transforming growth factor-beta receptor type I gene is frequently mutated in ovarian carcinomas. Cancer Res 61: 4679-4682, 2001. (Pubitemid 32691875)
34. Francis-Thickpenny KM, Richardson DM, van Ee CC, et al: Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma. Br J Cancer 85: 687-691, 2001. (Pubitemid 32929466)
35. Nakanishi Y, Kodama J, Yoshinouchi M, et al: The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. Int J Gynecol pathol 16: 256-262, 1997. (Pubitemid 27282300)
36. Sonmezer M, Gungor M, Ensari A and Ortac F: Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Int J Gynecol Cancer 14: 82-88, 2004. (Pubitemid 38280627)
37. Carey MS, Agarwal R, Gilks B, et al: Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 16: 2852-2860, 2010.
38. Helleman J, Jansen MP, Burger C, van der Burg ME and Berns EM: Integrated genomics of chemotherapy resistant ovarian cancer: a role for extracellular matrix, TGFbeta and regulating microRNAs. Int J Biochem Cell Biol 42: 25-30, 2010.
39. Sunde JS, Donninger H, Wu K, et al: Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66: 8404-8412, 2006. (Pubitemid 44449151)